Publications by authors named "J Tayek"
Background: Numerous studies demonstrate associations between serum concentrations of 25-hydroxyvitamin D (25[OH]D) and a variety of common disorders, including musculoskeletal, metabolic, cardiovascular, malignant, autoimmune, and infectious diseases. Although a causal link between serum 25(OH)D concentrations and many disorders has not been clearly established, these associations have led to widespread supplementation with vitamin D and increased laboratory testing for 25(OH)D in the general population. The benefit-risk ratio of this increase in vitamin D use is not clear, and the optimal vitamin D intake and the role of testing for 25(OH)D for disease prevention remain uncertain.
View Article and Find Full Text PDFDistinguishing between alcohol-associated hepatitis (AH) and alcohol-associated cirrhosis (AC) remains a diagnostic challenge. In this study, we used machine learning with transcriptomics and proteomics data from liver tissue and peripheral mononuclear blood cells (PBMCs) to classify patients with alcohol-associated liver disease. The conditions in the study were AH, AC, and healthy controls.
View Article and Find Full Text PDFArticle Synopsis
- - The study, EVAPORATE, aimed to assess the impact of icosapent ethyl (IPE) on coronary plaque characteristics in patients already on statin therapy, focusing on individual-level changes rather than just overall group results.
- - A total of 55 patients were randomized to receive either IPE or a placebo, with plaque morphology analyzed through advanced imaging techniques that measured factors like lipid-rich necrotic core size and fibrous cap thickness at 9 and 18 months.
- - Results showed that patients taking IPE experienced a significant reduction in lipid-rich necrotic core size compared to placebo, indicating potential benefits in plaque stability, while additional changes in wall and cap thickness suggested a more complex, individualized response to treatment
Background: In trials conducted in India, recombinant granulocyte colony stimulating factor (GCSF) improved survival in alcohol-associated hepatitis (AH). The aim of this trial was to determine the safety and efficacy of pegfilgrastim, a long-acting recombinant GCSF, in patients with AH in the United States.
Methods: This prospective, randomized, open label trial conducted between March 2017 and March 2020 randomized patients with a clinical diagnosis of AH and a Maddrey discriminant function score ≥32 to standard of care (SOC) or SOC+pegfilgrastim (0.